Evidence map›Paper›PMID 32982233›Full record

ArticleInternational journal of nanomedicine2020

PEG-Ceramide Nanomicelles Induce Autophagy and Degrade Tau Proteins in N2a Cells.

Jie Gao, Xiaohan Chen, Tianjun Ma, Bin He, Peng Li, Yucheng Zhao, Yuejin Ma, Jianhua Zhuang, You Yin

Open access · goldAbstract read
In one paragraph

Article in International journal of nanomedicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
2.0field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 26 citations in OpenAlex.

  1. Review
  2. Review
  3. The connection between autophagy and Alzheimer's disease.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2025
    Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. The application of nanotechnology in treatment of Alzheimer's disease.Frontiers in bioengineering and biotechnology · 2022
    Review
  13. Review
  14. Fluorescent Protein-Based Autophagy Biosensors.Materials (Basel, Switzerland) · 2021
    Review
  15. Nanomedicine: A Promising Way to Manage Alzheimer's Disease.Frontiers in bioengineering and biotechnology · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Jie Gao *Department of Neurology, Changzheng Hospital, Second Military Medical University, Shanghai 200003, People's Republic of China.
Xiaohan Chen *Department of Neurology, Changzheng Hospital, Second Military Medical University, Shanghai 200003, People's Republic of China.
Tianjun Ma *Department of Neurology, Changzheng Hospital, Second Military Medical University, Shanghai 200003, People's Republic of China.
Bin HeDepartment of Neurology, Changzheng Hospital, Second Military Medical University, Shanghai 200003, People's Republic of China.
Peng LiDepartment of Neurology, Changzheng Hospital, Second Military Medical University, Shanghai 200003, People's Republic of China.
Yucheng ZhaoDepartment of Neurology, Changzheng Hospital, Second Military Medical University, Shanghai 200003, People's Republic of China.
Yuejin MaDepartment of Neurology, Changzheng Hospital, Second Military Medical University, Shanghai 200003, People's Republic of China.
Jianhua ZhuangDepartment of Neurology, Changzheng Hospital, Second Military Medical University, Shanghai 200003, People's Republic of China.
You YinDepartment of Neurology, Changzheng Hospital, Second Military Medical University, Shanghai 200003, People's Republic of China.
Second Military Medical University · CNShanghai University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeAlzheimer's disease (AD) is a neurodegenerative disorder that manifests as abnormal behavior and a progressive decline in memory. Although the pathogenesis of AD is due to the excessive deposition of amyloid β protein (Aβ) outside the neurons in the brain, evidence suggests that tau proteins may be a better target for AD therapy. In neurodegenerative diseases, a decrease in autophagy results in the failure to eliminate abnormally deposited or misfolded proteins. Therefore, induction of autophagy may be an effective way to eliminate tau proteins in the treatment of AD. We investigated the effects of polyethylene glycol (PEG)-ceramide nanomicelles on autophagy and on tau proteins in N2a, a murine neuroblastoma metrocyte cell line.

methodsCeramide is a sphingolipid bioactive molecule that induces autophagy. PEG-ceramide is a polymer that is composed of the hydrophobic chain of ceramide and the hydrophilic chain of PEG-2000. In this study, we prepared PEG-ceramide nanomicelles that were 10-20 nm in size and had nearly neutral zeta potential.

resultsThe results show that PEG-ceramide nanomicelles caused an increase in the LC3-II/LC3-I ratio, while p62 protein levels decreased. Confocal microscopy revealed a significant increase in the number of dots corresponding to autophagosomes and autolysosomes, which indicated autophagic activation. Moreover, PEG-ceramide nanomicelles induced tau degradation in N2a cells through autophagy.

conclusionIn summary, we have confirmed that PEG-ceramide nanomicelles enhanced autophagic flux and degraded overexpressed human tau proteins in N2a cells by regulating the autophagy pathway. Thus, PEG-ceramide nanomicelles show great promise as agents to induce autophagy and degrade tau proteins in the treatment of AD.

Indexed as

Alzheimer DiseaseAnimalsAutophagosomesAutophagyBrain NeoplasmsCell Line, TumorCeramidesHumansLysosomesMiceMicrotubule-Associated ProteinsNanostructuresNeuroblastomaNeuronsPolyethylene Glycolstau ProteinsCeramidesMap1lc3b protein, mouseMicrotubule-Associated ProteinsPolyethylene Glycolstau ProteinsAlzheimer’s diseaseautophagic fluxautophagosomeslysosomenano-carrier

Identifiers

PMID32982233
PMCPMC7494393
OpenAlexW3084306022

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.